You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Phase Ib/II open-label, randomised evaluation of atezolizumab▼ (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
The MORPHEUS platform consists of multiple Phase Ib/II trials designed to identify early efficacy signals and safety of treatment combinations across several indications. The combination of atezolizumab▼ + CPI-444 versus docetaxel was evaluated as second- or third-line therapy in patients with metastatic non-small-cell lung cancer (NSCLC) who progressed on or after treatment with a platinum-containing regimen and PD-L1/PD-1 checkpoint inhibitor. Analyses included assessments of ongoing response, safety, pharmacokinetics and biomarker data across both arms.
Request medical material
Would you like to receive this poster via email to view later?